Summary
No FDA label support was provided for either patent/timeline claim, and the supplied prescribing information excerpts do not address intellectual property, patent filing/grant history, or follow-on patent scope.
Category Scores
Accurate Statements
Unsupported Statements
Xtampza ER (extended-release oxycodone) received its earliest patent protection in 2011.
The provided FDA-approved prescribing information excerpts contain no statements regarding patent protection dates or intellectual property history.
Xtampza can have additional follow-on patents covering formulation tweaks, manufacturing methods, or new combinations.
The provided FDA-approved prescribing information excerpts contain no statements regarding the existence, scope, or likelihood of follow-on patents or what topics such patents may cover.
Contradictions
Important Omissions
If the intent was to evaluate product-specific safety, efficacy, dosing/administration, contraindications, boxed warnings, or drug interactions claims, no such content was provided in the AI claims to compare against the label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims concern patent protection rather than prescribing/safety information; no direct medication risk statements were made in the provided AI claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Both claims are not supported by the provided FDA label excerpts and relate to intellectual property rather than prescribing information.
Suggested Improvement
Reframe the response to only include statements that are explicitly supported by the prescribing information (e.g., indication, dosing/administration instructions, contraindications, boxed warnings, specific warnings/precautions, drug interactions, and labeled use in populations).